Everolimus (RAD001)
Everolimus (RAD001) structure
|
Common Name | Everolimus (RAD001) | ||
|---|---|---|---|---|
| CAS Number | 159351-69-6 | Molecular Weight | 958.224 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 998.7±75.0 °C at 760 mmHg | |
| Molecular Formula | C53H83NO14 | Melting Point | NA | |
| MSDS | Chinese USA | Flash Point | 557.8±37.1 °C | |
| Symbol |
GHS02, GHS07 |
Signal Word | Danger | |
|
Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.
Antimicrob. Agents Chemother. 59(2) , 1088-99, (2015) Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure. Globally, MERS-CoV has been responsible for 877 laboratory-confirmed infections... |
|
|
Deproteination of whole blood for LC–MS/MS using paramagnetic micro-particles
Clin. Biochem. 47(15) , 112-5, (2014) Objectives Liquid chromatography tandem mass spectrometry has become increasingly popular in clinical laboratories over the last decade due to the inherent sensitivity and specificity of the technology. Nevertheless, full automation and hence application in r... |
|
|
A direct method for the measurement of everolimus and sirolimus in whole blood by LC-MS/MS using an isotopic everolimus internal standard.
Ther. Drug Monit. 36(3) , 358-65, (2014) Whole-blood concentrations of the immunosuppressant drugs everolimus and sirolimus should be monitored. A sensitive and selective method offering the detection of both analytes in small sample volumes would optimize the throughput of samples for sirolimus or ... |
|
|
Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Transplantation 99(1) , 180-6, (2015) Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing strategy in de novo renal transplant recipients.A comparative... |
|
|
The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.
Clin. Transplant. 28(8) , 845-54, (2014) Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and other immunosuppression on the risk of recurrent IgAN post-k... |
|
|
The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Ann. Transplant. 19 , 337-45, (2014) Pharmacokinetic data regarding a drug-drug interaction between everolimus and tacrolimus are sparse.In a pharmacokinetic substudy of the randomized ASSET trial, 46 de novo kidney transplant patients receiving very low (1.5-3 ng/mL) or low (4-7 ng/mL) tacrolim... |
|
|
Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Transplant. Proc. 46(10) , 3496-501, (2014) Liver transplantation offers the most effective treatment in patients with hepatocellular carcinoma (HCC). However, transplant patients outside the Milan criteria have a high risk of tumor recurrence, which has been linked to standard immunosuppression regime... |
|
|
Effects of everolimus on oxidative stress in kidney model of ischemia/reperfusion injury.
Am. J. Nephrol. 37(4) , 291-301, (2013) Reactive oxygen species play an important role in the pathogenesis of kidney ischemia/reperfusion injury (IRI) which may be influenced by immunosuppressive therapy. Pertinent to this, we investigated the effects of the mTOR inhibitor everolimus on redox setti... |
|
|
The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Cancer Biol. Ther. 15(11) , 1552-60, (2014) BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates to short term tumor growth inhibition. We sought to identify the molecular and cellular events activ... |
|
|
Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells.
J. BUON 19(2) , 466-73, (2014) To investigate the effects of autophagy on growth inhibition by gefitinib in non-small cell lung cancer (NSCLC) cell lines and its probable mechanism.The mRNA and protein levels of Beclin 1, authophagy related 5 (Atg5) and Atg7 were assessed. H460 and Calu6 N... |